Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that it will showcase 46 abstracts, ...
Cumberland Pharmaceuticals Inc. , a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $8.3 million during the third ...
Ustekinumab and vedolizumab have comparable safety and efficacy in older and younger adults with IBD, indicating that age should not be a deterrent for treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback